Profile data is unavailable for this security.
About the company
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The Company has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).
- Revenue in USD (TTM)2.22m
- Net income in USD-54.81m
- Incorporated2021
- Employees38.00
- LocationUpstream Bio Inc890 Winter Street, Suite 200WALTHAM 02451United StatesUSA
- Phone+1 (781) 208-2466
- Fax+1 (302) 636-5454
- Websitehttps://upstreambio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CareDx Inc | 312.78m | -143.56m | 1.25bn | 635.00 | -- | 4.53 | -- | 4.00 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Cassava Sciences Inc | 0.00 | -17.66m | 1.27bn | 29.00 | -- | 7.59 | -- | -- | -0.3772 | -0.3772 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -8.91 | -30.74 | -10.98 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Vir Biotechnology Inc | 78.62m | -533.34m | 1.27bn | 587.00 | -- | 1.02 | -- | 16.20 | -3.92 | -3.92 | 0.5794 | 9.08 | 0.0444 | -- | -- | 133,931.90 | -30.10 | -0.6081 | -32.71 | -0.7192 | 98.78 | -- | -678.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Enliven Therapeutics Inc | 0.00 | -82.83m | 1.28bn | 52.00 | -- | 4.20 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Novavax Inc | 987.67m | -294.33m | 1.35bn | 1.54k | -- | -- | -- | 1.37 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Syndax Pharmaceuticals Inc | 16.00m | -297.06m | 1.38bn | 112.00 | -- | 3.79 | -- | 86.48 | -3.63 | -3.63 | 0.1949 | 4.28 | 0.0388 | -- | 3.60 | 142,857.10 | -72.01 | -27.90 | -81.78 | -30.15 | -- | -- | -1,856.64 | -324.34 | -- | -- | 0.00003 | -- | -- | -- | -40.19 | -- | -- | -- |
| Upstream Bio Inc | 2.22m | -54.81m | 1.41bn | 38.00 | -- | -- | -- | 636.60 | -1.07 | -1.07 | 0.0433 | 4.56 | -- | -- | -- | 63,457.14 | -- | -- | -- | -- | -- | -- | -1,823.82 | -- | -- | -- | 0.00 | -- | 96.37 | -- | -60.28 | -- | -- | -- |
| Maravai Lifesciences Holdings Inc | 278.59m | -132.08m | 1.44bn | 580.00 | -- | 3.29 | -- | 5.16 | -0.998 | -0.998 | 2.09 | 1.73 | 0.1501 | 3.07 | 6.36 | 428,592.30 | -8.74 | 12.67 | -11.38 | 15.46 | 46.73 | 74.79 | -58.24 | 37.32 | 9.28 | -1.59 | 0.4167 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Kura Oncology Inc | 0.00 | -197.55m | 1.44bn | 142.00 | -- | 3.41 | -- | -- | -2.36 | -2.36 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -41.48 | -26.04 | -44.66 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0219 | -- | -- | -- | -12.36 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -258.08m | 1.46bn | 268.00 | -- | 4.43 | -- | -- | -2.75 | -2.75 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -52.01 | -35.26 | -56.17 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0605 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Gyre Therapeutics Inc | 165.85m | -79.66m | 1.50bn | 593.00 | -- | 22.69 | -- | 9.02 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Arcus Biosciences Inc | 263.00m | -270.00m | 1.53bn | 577.00 | -- | 2.72 | -- | 5.84 | -3.15 | -3.15 | 3.06 | 6.17 | 0.2153 | -- | 6.83 | 455,805.90 | -22.10 | -15.85 | -26.63 | -18.25 | -- | -- | -102.66 | -103.46 | -- | -- | 0.0768 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Praxis Precision Medicines Inc | 1.61m | -151.02m | 1.55bn | 82.00 | -- | 3.86 | -- | 963.47 | -10.29 | -10.29 | 0.1058 | 21.52 | 0.0061 | -- | -- | 19,573.17 | -57.75 | -74.04 | -63.81 | -85.12 | -- | -- | -9,409.22 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Day One Biopharmaceuticals Inc | 101.95m | -84.29m | 1.58bn | 174.00 | -- | 2.84 | -- | 15.47 | -1.02 | -1.02 | 1.14 | 5.51 | 0.2009 | -- | -- | 657,761.30 | -16.61 | -- | -17.73 | -- | 97.75 | -- | -82.68 | -- | 14.55 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Travere Therapeutics Inc | 203.45m | -348.96m | 1.61bn | 380.00 | -- | -- | -- | 7.90 | -4.52 | -4.56 | 2.63 | -0.3909 | 0.3043 | 0.7192 | 10.24 | 535,386.80 | -52.19 | -36.95 | -69.25 | -44.77 | 95.21 | 95.92 | -171.52 | -165.79 | 1.68 | -- | 1.09 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Data as of Nov 13 2024. Currency figures normalised to Upstream Bio Inc's reporting currency: US Dollar USD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Altshuler Shaham Provident Funds & Pension Ltd. (Invt Mgmt)as of 11 Oct 2024 | 3.39m | 0.00% |
| Wellington Management Co. LLPas of 15 Oct 2024 | 894.73k | 0.00% |
Data from 30 Jun 2024 - 14 Oct 2024Source: FactSet Research Systems Inc.
